|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
KR102726248B1
(ko)
|
2016-07-07 |
2024-11-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
MX2020012679A
(es)
*
|
2018-05-25 |
2021-02-09 |
Silverback Therapeutics Inc |
Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
|
|
CN111018857B
(zh)
*
|
2018-10-09 |
2023-06-02 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
CN119684457A
(zh)
|
2018-11-26 |
2025-03-25 |
四十七有限责任公司 |
针对c-kit的人源化抗体
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
WO2020231809A1
(en)
*
|
2019-05-10 |
2020-11-19 |
Lyvgen Biopharma Co., Ltd. |
Humanized anti-cd137 antibodies and uses thereof
|
|
WO2020236875A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Therapeutics, Inc. |
Madcam targeted immunotolerance
|
|
WO2021013068A1
(en)
*
|
2019-07-19 |
2021-01-28 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Polypeptide complex for conjugation and use thereof
|
|
WO2021023117A1
(zh)
*
|
2019-08-02 |
2021-02-11 |
康方药业有限公司 |
抗ctla4-抗pd-1双特异性抗体及其用途
|
|
WO2021102332A1
(en)
*
|
2019-11-22 |
2021-05-27 |
Silverback Therapeutics, Inc. |
Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
|
|
AU2020402752A1
(en)
*
|
2019-12-12 |
2022-06-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for CD276 and uses thereof
|
|
AU2021205893A1
(en)
*
|
2020-01-08 |
2022-06-23 |
Synthis Therapeutics, Inc. |
ALK5 inhibitor conjugates and uses thereof
|
|
TWI854088B
(zh)
*
|
2020-01-27 |
2024-09-01 |
英商梅迪繆思有限公司 |
用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
CA3174263A1
(en)
*
|
2020-04-01 |
2021-10-07 |
Hans David Ulmert |
Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
|
|
CN113509557A
(zh)
*
|
2020-04-09 |
2021-10-19 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
EP4149627A4
(en)
*
|
2020-05-14 |
2024-05-29 |
The General Hospital Corporation |
POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
|
|
WO2021243136A2
(en)
*
|
2020-05-29 |
2021-12-02 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery |
Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis
|
|
IL298695A
(en)
*
|
2020-06-02 |
2023-02-01 |
Childrens Medical Center |
Nanobody conjugates (VHH) and their uses
|
|
JP2023532304A
(ja)
|
2020-07-01 |
2023-07-27 |
エーアールエス ファーマシューティカルズ オペレーションズ，インク． |
抗ａｓｇｒ１抗体コンジュゲートおよびその使用
|
|
KR102506295B1
(ko)
*
|
2020-08-28 |
2023-03-08 |
국립암센터 |
디그옥시제닌에 대한 인간화 항체 및 이의 용도
|
|
CN114146095A
(zh)
*
|
2020-09-07 |
2022-03-08 |
是光隽恒(北京)生物科技有限公司 |
用于组织损伤修复的组合物及其制备方法和用途
|
|
WO2022053864A1
(en)
*
|
2020-09-08 |
2022-03-17 |
Kwon Byoung S |
Pd-1 polypeptide variants
|
|
EP4247434A4
(en)
*
|
2020-11-18 |
2024-10-23 |
Pandion Operations, Inc. |
THERAPEUTIC AGENTS TARGETING MADCAM AND THEIR USES
|
|
AU2022254042A1
(en)
*
|
2021-04-07 |
2023-09-14 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and antibodies and uses thereof
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
AU2022304258A1
(en)
|
2021-07-02 |
2024-02-15 |
Merck Patent Gmbh |
Anti-protac antibodies and complexes
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
EP4444759A4
(en)
*
|
2021-12-09 |
2025-11-26 |
Genequantum Healthcare Suzhou Co Ltd |
ANTIBODY-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
|
|
US20260055119A9
(en)
*
|
2021-12-30 |
2026-02-26 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Tricyclic compound, method for preparing same, and use thereof
|
|
AU2023347072A1
(en)
*
|
2022-09-20 |
2025-01-02 |
Currus Biologics Pty Ltd |
Bispecific polypeptides and uses thereof
|
|
EP4637833A2
(en)
*
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
KR20250129729A
(ko)
|
2022-12-27 |
2025-08-29 |
메르크 파텐트 게엠베하 |
Vhh 항-protac 항체 및 복합체
|
|
FR3147278A1
(fr)
*
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
FR3147292A1
(fr)
*
|
2023-03-31 |
2024-10-04 |
Affyxell Therapeutics Co., Ltd. |
Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
|
|
EP4688825A1
(en)
*
|
2023-03-31 |
2026-02-11 |
AffyXell Therapeutics Co., Ltd. |
Tnfr2 binding polypeptides and methods of use
|
|
TW202500195A
(zh)
*
|
2023-05-18 |
2025-01-01 |
美商飛爾富來生物公司 |
異吲哚啉酮－戊二醯亞胺抗體結合物及其用途
|
|
WO2024243545A1
(en)
*
|
2023-05-24 |
2024-11-28 |
President And Fellows Of Harvard College |
Compositions targeting endothelial cells and uses thereof
|
|
AU2024353316A1
(en)
|
2023-09-26 |
2026-03-26 |
Genmab A/S |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
EP4595981A1
(en)
*
|
2024-02-01 |
2025-08-06 |
Jack Elands |
Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody
|
|
WO2025163120A1
(en)
*
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025216667A1
(en)
*
|
2024-04-12 |
2025-10-16 |
Joint Stock Company «Biocad» |
Monoclonal antibody that specifically binds to bdca-2
|